Puma Biotech (PBYI) Tops Q4 EPS by 1c, offers outlook

Puma Biotech (NASDAQ: PBYI) reported Q4 EPS of $0.31, $0.01 better than the analyst estimate of $0.30. Revenue for the quarter came in at $72.2 million versus the consensus estimate of $73.55 million.

Outlook Q1 2024:

Net Product Revenue: $38 - $40 million.
Royalty Revenue: $2.5 - $3 million
License Revenue:$0 million

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• The Lovesac Company (LOVE) Tops Q1 EPS by 29c